Product Description
Retatrutide is an investigational triple-receptor agonist (targeting GLP-1, GIP, and glucagon receptors) primarily evaluated for weight management and type 2 diabetes. Products like the Synedica Retatrutide prefilled pen are non-FDA-approved, unlicensed peptide products. Because it is not an officially approved commercial medication with standardized delivery systems, explicit instructions depend entirely on the specific research protocol or source supplier guidelines.
Retatrutide is an investigational triple-receptor agonist (targeting GLP-1, GIP, and glucagon receptors) primarily evaluated for weight management and type 2 diabetes. Products like the Synedica Retatrutide prefilled pen are non-FDA-approved, unlicensed peptide products. Because it is not an officially approved commercial medication with standardized delivery systems, explicit instructions depend entirely on the specific research protocol or source supplier guidelines.